{"id":"W4391095740","doi":"10.1200/jco.2024.42.3_suppl.129","title":"A first-in-human, open-label, phase I trial of daily oral zelenirstat, an NMT inhibitor, in patients with relapsed/refractory advanced cancer including gastrointestinal cancers.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Nausea; Tolerability; Internal medicine; Adverse effect; Gastroenterology; Cancer; Vomiting; Refractory (planetary science); Colorectal cancer; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002397999,0.000298775,0.002216741,0.0004248633,0.00005135993,0.00002295114,0.0004004762,0.0002251136,0.0001375302],"category_scores_gemma":[0.001145726,0.0002224524,0.0001567927,0.0005143763,0.0003991589,0.0009542356,0.0001363307,0.001985232,0.000001560736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00175619,"about_ca_system_score_gemma":0.005175874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004430269,"about_ca_topic_score_gemma":0.003334667,"domain_scores_codex":[0.9947895,0.0004135224,0.003247493,0.0004679135,0.0006136034,0.0004679634],"domain_scores_gemma":[0.9959031,0.0009961572,0.001858278,0.0002867954,0.0005566356,0.0003990069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.62791,0.01466408,0.09050667,0.0002132599,0.0002460873,0.00160615,0.000623332,0.0006367762,0.0009810107,0.00008131604,0.000238795,0.2622925],"study_design_scores_gemma":[0.6893762,0.2107609,0.07147308,0.005989053,0.0003232603,0.0001758755,0.0003905701,0.0003893581,0.00009841306,0.000547089,0.02011757,0.0003585971],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951681,0.0008612617,0.000156949,0.001229385,0.001468892,0.0008732949,0.00002571271,0.00001687535,0.0001995534],"genre_scores_gemma":[0.9876557,0.0002356803,0.01057223,0.000430027,0.0009316355,0.00004556127,0.000008679332,0.00006143661,0.00005906311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.261934,"threshold_uncertainty_score":0.9181777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1394459851429618,"score_gpt":0.5023822377590372,"score_spread":0.3629362526160754,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}